Famprya (fampridine) is set to be rejected by The National Institute for Health and Care Excellence (NICE) in England for use on the NHS for people with multiple sclerosis (MS). NICE will recommend against the drug as it says it is not cost effective.
Famprya has been shown to improve walking difficulties, with around one in three people saying their walking speed improves by about 25%.
The medication is taken as a tablet twice daily. It has already been approved for use on the NHS in Wales and Scotland.
The latest from NICE is a draft guideline and it is currently possible to comment on the proposal here. NICE does acknowledge Famprya is clinically effective, but says that it is not cost edffective.
Source: MS-UK 21 December 2021